Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma

Shinya Sakata; Sho Saeki; Ryo Sato; Shiho Ishizuka; Jiichiro Sasaki; Kazuhiko Fujii

doi:10.1016/j.resinv.2017.08.005

Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma

Respir Investig. 2017 Nov;55(6):372-375. doi: 10.1016/j.resinv.2017.08.005. Epub 2017 Oct 6.

Authors

Shinya Sakata¹, Sho Saeki², Ryo Sato¹, Shiho Ishizuka¹, Jiichiro Sasaki³, Kazuhiko Fujii¹

Affiliations

¹ Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
² Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. Electronic address: saeshow@wg7.so-net.ne.jp.
³ Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan.

PMID: 29153418
DOI: 10.1016/j.resinv.2017.08.005

Abstract

We report the case of a 62-year-old Japanese male with metastatic spindle cell carcinoma (SpCC) who showed a long-term complete response (CR) to bevacizumab combination chemotherapy. We performed chemotherapy with carboplatin (AUC 6, day 1) plus paclitaxel (200mg/m², day 1) plus bevacizumab (15mg/kg, day 1) for four cycles. After the chemotherapy, CT imaging demonstrated a CR. We subsequently administered bevacizumab (15mg/kg) repeated every 3 weeks as maintenance therapy for 12 cycles. The patient discontinued maintenance chemotherapy because of grade 3 proteinuria, but the anti-tumor effect of CR was maintained at 35 months after the discontinuation of chemotherapy.

Keywords: Bevacizumab; Carboplatin; Complete response; Paclitaxel; Spindle cell carcinoma.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / administration & dosage
Bevacizumab / adverse effects
Bone Neoplasms / secondary
Carboplatin / administration & dosage
Carboplatin / adverse effects
Carcinoma / diagnostic imaging
Carcinoma / drug therapy*
Carcinoma / pathology
Carcinoma / secondary
Drug Administration Schedule
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lymphatic Metastasis
Maintenance Chemotherapy
Male
Middle Aged
Neoplasm Invasiveness
Paclitaxel / administration & dosage
Paclitaxel / adverse effects
Pleural Neoplasms / secondary
Proteinuria / chemically induced
Tomography, X-Ray Computed
Treatment Outcome
Withholding Treatment

Substances

Bevacizumab
Carboplatin
Paclitaxel